Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyMeridian Health Plan Actimmune Prior Auth Coverage…
    Ask Trek AI about this page
    Currentmeridian_health_plan_of_michiganPolicy N/A

    Actimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteria

    Customize your policy alerts

    Sign up for all meridian_health_plan_of_michigan policy alerts

    Know when meridian_health_plan_of_michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and coverage criteria for Actimmune for Meridian Health Plan of Michigan members, including indications, prescriber and testing requirements, and coverage duration.

    Policy Summary
    Payermeridian_health_plan_of_michigan
    PolicyActimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document diagnostic confirmation (molecular genetic test for CGD or radiographic evidence for malignant osteopetrosis) to support a 1-year approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All FDA-approved Indicationsindications listed for coverage
    1 yearstandard coverage duration
    Specialist requiredprescriber restrictions (CGD/osteopetrosis)
    Genetic/X-ray

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    diagnosis verification

    Coverage Criteria and Clinical Requirements

    Initial Approval Criteria

    Approve Actimmune for listed indications when ALL of the following are met:

    Initial Approval for Chronic Granulomatous Disease: Diagnosis of chronic granulomatous disease established by a molecular genetic test identifying a gene-related pathogenic variant linked to chronic granulomatous disease.

    Prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist.

    Initial Approval for Malignant Osteopetrosis, Severe

    Approve Actimmune when ALL of the following are met:

    Initial Approval for Malignant Osteopetrosis: Patient has malignant osteopetrosis, severe with radiographic (X-ray) imaging demonstrating skeletal features related to malignant osteopetrosis.

    Prescribed by or in consultation with an endocrinologist or hematologist.

    General Approval Conditions

    Coverage Duration: Approval duration is 1 year for covered indications.

    Indications include all FDA-approved indications.

    ALK-positive oncology indications (partial)

    Coverage for ALK-targeted and related oncology indications is allowed when specified disease and biomarker criteria are met.

    NSCLC - Alunbrig (excerpt): Approve if patient has both (A and B): A) either (i) medication is used as adjuvant treatment following tumor resection (tumor >= 4 cm or node positive) or (ii) advanced or metastatic disease; AND B) ALK-positive disease as detected by an approved test.

    from chunk 18

    Alunbrig step therapy

    Alunbrig-specific additional criteria (excerpt).

    Alunbrig prior therapy: For NSCLC patients new to therapy must have a trial of Alecensa, Ensacove or Lorbrena prior to approval of Alunbrig.

    from chunk 25

    Arcalyst initial and continuation therapy

    Arcalyst (IL-1 blockade) initial and continuation therapy criteria (excerpt).

    DIRA initial therapy: Confirmed bi-allelic pathogenic variants in the IL1RN gene AND clinical benefit with anakinra subcutaneous injection.

    from chunk 36

    Pericarditis initial therapy: Pericarditis must be recurrent; prescriber specialty requirements apply.

    from chunk 36

    Continuation therapy: Patient had a positive response to therapy for all indications.

    from chunk 36

    Anti-obesity agents: initiation and renewal criteria

    Anti-obesity agent coverage criteria (excerpt).

    Initial non-GLP1 (ages 12-17): For ages 12-17: BMI >= 95th percentile OR BMI 85th-94th percentile with at least one weight-related comorbidity (diabetes, sleep apnea, hypertension, dyslipidemia).

    from chunk 33

    Initial non-GLP1 (ages 18+): For ages 18+: BMI >= 30 kg/m^2 OR BMI 27-29 kg/m^2 with at least one risk factor (hypertension, coronary artery disease, diabetes, dyslipidemia, sleep apnea).

    from chunk 33

    Initial GLP-1 criteria: Trial and failure of ALL five preferred agents (unless contraindication/intolerance) AND prescriber attests that failure of other interventions occurred, GLP-1 use is to avert bariatric surgery, AND initial BMI meets morbid obesity threshold (12-17 per CDC growth charts; 18+ BMI >= 40 kg/m^2).

    from chunks 33 and 34

    Renewal GLP-1:

    IV antifungals

    IV antifungals coverage (excerpt).

    Voriconazole IV: Coverage for IV voriconazole products for FDA-approved indications; required documentation: diagnosis.3 months coverage duration noted

    from chunk 29

    Alpha-1 proteinase inhibitors

    Alpha-1 antitrypsin replacement coverage (excerpt).

    Prolastin-C: Indicated for Alpha1-Antitrypsin Deficiency with emphysema and serum concentration < 80 mg/dL (11 micromol/L); coverage duration 1 year.serum concentration < 80 mg/dL

    from chunk 23

    Alosetron

    Alosetron coverage (excerpt).

    Alosetron: Authorization requires a diagnosis; age restriction 18 years and older; coverage duration 12 months.

    from chunk 21

    Actimmune/Arcalyst Initial and Continuation Criteria

    Initial and continuation therapy criteria summarized for Arcalyst/Actimmune indications (CAPS, DIRA, Pericarditis):

    Initial therapy - DIRA: Confirmed bi-allelic pathogenic variants in the IL1RN gene AND clinical benefit with anakinra subcutaneous injection

    From chunk 36

    Initial therapy - CAPS/Pericarditis: Age restrictions apply (CAPS/Pericarditis >= 12 years) AND prescriber restrictions apply (e.g., rheumatologist, geneticist, allergist/immunologist, dermatologist; cardiologist for pericarditis)

    From chunk 36

    Continuation therapy - All indications: Patient had a positive response to therapy

    From chunk 36

    Arikayce Initial Therapy

    Arikayce (for Mycobacterium avium complex [MAC] lung disease) initial therapy criteria — all must be met:

    Arikayce initial therapy: A) Positive sputum culture for MAC; AND B) MAC isolate susceptible to amikacin; AND C) Arikayce will be used in combination with abackground multidrug regimen (e.g., macrolide, ethambutol, rifamycin).

    From chunk 38

    Benlysta Coverage Criteria

    Benlysta subcutaneous criteria for SLE and lupus nephritis:

    Benlysta - Lupus Nephritis Initial: Biopsy-confirmed lupus nephritis (e.g., WHO class III, IV, or V) AND being used concurrently with an immunosuppressive regimen.

    From chunks 51-52

    Benlysta - SLE Initial: Autoantibody-positive SLE (positive ANA and/or anti-dsDNA) AND Benlysta used concurrently with at least one other standard therapy unless intolerant.

    From chunks 51-52

    Benlysta - Continuation: Medication is being used concurrently with at least one other standard therapy AND the patient has responded to Benlysta subcutaneous or intravenous.

    From chunk 52

    Besremi PA Criteria

    Besremi coverage notes:

    Besremi: PA required; indication must be an FDA-approved indication; prescribed by or in consultation with an oncologist or hematologist; age 18 years and older; coverage duration 1 year.

    From chunk 54; concomitant use with other interferon products is an exclusion.

    Besremi (Actimmune) Initial Authorization

    Covered when ALL of the following are met:

    Besremi (Actimmune) PA criteria: Indication: diagnosis required; Age: 18 years and older; Prescriber: prescribed by or in consultation with an oncologist or hematologist; Coverage duration: 1 year; Indications: FDA-approved indications.

    Concomitant use with other interferon products is an exclusion.

    Betaseron Initial Authorization

    Covered when ALL of the following are met:

    Betaseron PA criteria: Diagnosis: relapsing form of multiple sclerosis (including clinically-isolated syndrome, relapsing-remitting disease, active secondary progressive); Prescriber: prescribed by or after consultation with a neurologist or MS specialist; Coverage duration: 1 year; Exclusion: concurrent use with other disease-modifying agents for MS.

    From chunk 56

    Brinsupri Initial and Continuation Therapy

    BRONCHIECTASIS, NON-CYSTIC FIBROSIS - Covered when ALL of the following are met:

    Brinsupri initial criteria: A. History of bronchiectasis as diagnosed by chest CT; AND B. ONE of: (i) age 12-17 with >=1 pulmonary exacerbation in last 12 months requiring antibiotics, OR (ii) >=18 years with >=2 pulmonary exacerbations in last 12 months requiring antibiotics; AND C. Respiratory symptoms not driven primarily by COPD or asthma; AND D. Does not have cystic fibrosis.

    From chunks 68-69

    Brinsupri continuation criteria: A. Does not have cystic fibrosis; AND B. Experienced a beneficial clinical response (examples: reduced exacerbations, preserved lung function, reduced cough/sputum/shortness of breath).

    From chunks 68-69

    Bosentan PAH / CTEPH Criteria

    Covered when ALL of the following are met:

    Bosentan PAH criteria: Diagnosis: pulmonary arterial hypertension (PAH) WHO Group 1 with right-heart catheterization confirmation; Prescriber: prescribed by or in consultation with a cardiologist or pulmonologist; Coverage duration: 1 year.

    For CTEPH, patient must have tried Adempas, have a contraindication to Adempas, or be currently receiving bosentan.

    Braftovi Indication-Specific Criteria

    Covered when ALL of the following are met (by indication):

    Braftovi melanoma: Indication: unresectable, advanced or metastatic melanoma AND BRAF V600 mutation-positive; Age: 18 years and older; Coverage duration: 1 year.

    From chunk 66

    Braftovi colon/rectal: Indication: BRAF V600E mutation-positive colon or rectal cancer AND (A) used first-line in combination with cetuximab/panitumumab plus FOLFOX, OR (B) previously received chemo and used in combination with cetuximab/panitumumab.

    From chunk 66

    Braftovi NSCLC: Indication: BRAF V600E mutation-positive recurrent, advanced or metastatic NSCLC AND used in combination with binimetinib.

    From chunk 66

    Brukinsa Indication-Specific Criteria

    Covered when ALL of the following are met (by disease):

    Brukinsa follicular lymphoma: Patient has follicular lymphoma and has tried at least two other systemic regimens and will use Brukinsa in combination with obinutuzumab.

    From chunks 71-72

    Brukinsa mantle cell lymphoma: Approve if patient meets A or B: A) tried Calquence or Imbruvica AND (1) tried at least one other line of systemic regimen OR (2) is not a candidate for chemotherapy OR (3) will use in combination with rituximab; OR B) patient has TP53 mutation and Brukinsa used as induction with venetoclax and obinutuzumab.

    From chunks 71-72

    Brukinsa CLL/SLL: Approve if patient has tried Calquence or Imbruvica.

    From chunks 71-72

    Haegarda coverage criteria

    Haegarda (C1 esterase inhibitor) — Prophylaxis

    HAE Type I or II — Initial Therapy: Approve if the patient has HAE type I or type II confirmed by low functional C1-INH protein (<50% of normal) at baseline AND lower-than-normal serum C4 levels at baseline.functional C1-INH <50%

    chunk 74

    HAE Type I or II — Continuation Therapy: If patient is currently taking Haegarda for prophylaxis approve if (i) patient has diagnosis of HAE type I or II AND (ii) prescriber documents favorable clinical response since initiating Haegarda compared with baseline.

    chunk 74

    HAE with Normal C1-INH (Type III) — Prophylaxis: Approve if EITHER: 1) patient tested positive for a mutation in F12, ANGPT1, PLG, KNG1, HS3ST6, or MYOF OR 2) patient has family history of angioedema and angioedema refractory to high-dose antihistamine therapy for >=1 month.

    chunk 74

    Cabometyx coverage criteria

    Cabometyx (multi-indication oncology agent)

    Renal Cell Carcinoma: Approve if patient has relapsed or stage IV disease.

    chunk 78

    Hepatocellular Carcinoma: Approve if patient has been previously treated with at least one other systemic therapy (e.g., Nexavar, Lenvima).

    chunk 78

    Bone cancer: Approve if patient has Ewing sarcoma or osteosarcoma AND has tried at least one previous systemic regimen.

    chunk 78

    Thyroid carcinoma: Approve for differentiated thyroid carcinoma refractory to radioactive iodine AND patient has tried Lenvima or sorafenib.

    chunk 78

    Calquence coverage criteria

    Calquence

    Mantle Cell Lymphoma: Approve if patient has tried at least one systemic regimen or is not a candidate for systemic therapy; note it may be used in combination with rituximab.

    chunk 81

    Marginal Zone Lymphoma: Approve if patient has tried at least one systemic regimen (examples listed).

    chunk 81

    Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: Approve if patient has tried at least one systemic regimen (examples listed).

    chunk 81

    Carglumic acid coverage criteria

    Carglumic acid

    N-Acetylglutamate synthase deficiency: Approve if genetic testing confirms a mutation leading to deficiency OR if the patient has hyperammonemia.

    chunk 85

    PA/MMA with hyperammonemia - acute treatment: Approve if plasma ammonia >= 50 micromol/L AND medication will be used with other ammonia-lowering therapies.plasma ammonia >= 50 micromol/L

    chunk 85

    Cayston coverage criteria

    Cayston

    Cayston indication: Approve if patient has Pseudomonas aeruginosa in airway culture (e.g., sputum, oropharyngeal, BAL).

    chunk 87

    Clobazam coverage criteria

    Clobazam

    Lennox-Gastaut initial therapy: Patient must have tried and/or be concomitantly receiving one of: lamotrigine, topiramate, rufinamide, felbamate, Fintepla, Epidiolex or valproic acid.

    chunk 89

    Treatment-refractory seizures initial therapy: Patient must have tried and/or be concomitantly receiving at least two other antiepileptic drugs (examples listed).

    chunk 89

    Continuation: Prescriber must confirm patient is responding to therapy for continued coverage.

    chunk 89

    Clomipramine coverage criteria

    Clomipramine

    Approved uses and prerequisites: Request meets either (1 and 2) OR (3 and 4): (1) drug is for OCD, Panic Disorder, or Autistic disorder AND (2) patient had inadequate response/intolerance/contraindication to an SNRI or an SSRI; OR (3) drug is for Depression AND (4) patient had inadequate response/intolerance/contraindication to two of: SNRIs, SSRIs, mirtazapine, bupropion.

    chunk 91

    Initial Therapy

    Approve when EITHER of the following combined condition sets are met:

    Pathway A (OCD/Panic/Autistic): (1) The requested drug is being prescribed for one of: Obsessive-Compulsive Disorder (OCD), Panic Disorder, Autistic disorder AND (2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one of the following: a serotonin and norepinephrine reuptake inhibitor (SNRI) OR a selective serotonin reuptake inhibitor (SSRI).
    Pathway B (Depression): (3) The requested drug is being prescribed for Depression AND (4) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to two of the following: SNRIs, SSRIs, mirtazapine, bupropion.

    Initial and Continuation Criteria

    Covered when ALL of the following are met

    Initial therapy: Patient is ambulatory; dalfampridine is being used to improve or maintain mobility in a patient with multiple sclerosis; patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25-foot walk, MSWS-12); prescriber is a neurologist or MS specialist (or prescribed in consultation with one); patient is age 18 years or older.

    Authorization duration: 1 year.

    Continuation therapy: Patient is ambulatory; dalfampridine is being used to improve or maintain mobility in a patient with multiple sclerosis; patient has responded to or is benefiting from therapy; prescriber is a neurologist or MS specialist (or prescribed in consultation with one); patient is age 18 years or older.

    Authorization duration: 1 year.

    Atopic Dermatitis (AD) - Initial Therapy

    Covered when ALL of the following are met

    AD initial: Approve for atopic dermatitis as stated in the policy.

    From chunk 126

    Asthma - Initial Therapy

    Covered when ALL of the following are met

    Asthma criteria: A) blood eosinophil >=150 cells/μL within previous 6 weeks or prior to Dupixent/another monoclonal antibody or oral corticosteroid-dependent asthma; B) patient used an inhaled corticosteroid plus at least one additional asthma controller; C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of: (a) >=2 exacerbations requiring oral corticosteroids in past year, (b) >=1 exacerbation requiring hospital/urgent care/ED in past year, (c) FEV1 <80% predicted (<90% if <18 years), (d) FEV1/FVC <0.8 (<0.9 if <18 years), or (e) worsened asthma with oral corticosteroid taper.eosinophil >=150 cells/μL

    from chunk 126

    COPD - Initial Therapy

    Covered when ALL of the following are met

    COPD criteria: A) blood eosinophil >=300 cells/μL within previous 6 weeks or prior to Dupixent/another monoclonal antibody, and B) received at least 3 months of combination therapy with at least two of LAMA, LABA or ICS, and C) either i) two or more COPD exacerbations in previous 12 months requiring systemic corticosteroids with or without antibiotics, or ii) COPD exacerbation requiring hospitalization in previous 12 months.eosinophil >=300 cells/μL

    from chunk 127

    Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - Initial Therapy

    Covered when ALL of the following are met

    CRSwNP criteria: A) concurrent use with nasal corticosteroid; B) presence of at least two symptoms for 8 weeks among nasal congestion/obstruction/discharge or reduction/loss of smell; C) received oral corticosteroids at least 5 days in last 2 years (unless contraindicated) or prior surgery for nasal polyps; D) diagnosis confirmed by direct exam, endoscopy, or sinus CT.symptom duration 8 weeks; oral CS >=5 days in 2 years

    from chunk 127

    Eosinophilic Esophagitis (EoE) - Initial Therapy

    Covered when ALL of the following are met

    EoE criteria: A) patient weighs >=15 kg; B) endoscopic biopsy demonstrating >=15 intraepithelial eosinophils per high-power field; C) no secondary cause of EoE; D) received a prescription-strength proton pump inhibitor for at least 8 weeks.biopsy >=15 eos/hpf; weight >=15 kg; PPI 8 weeks

    from chunk 127

    Prurigo Nodularis (PN) - Initial Therapy

    Covered when criterion is met

    PN criteria: Pruritus lasting at least 6 weeks.>=6 weeks

    from chunk 127

    Chronic Spontaneous Urticaria (CSU) - Initial Therapy

    Covered when criterion is met

    CSU criteria: Urticaria for greater than 6 weeks despite non-sedating H1 antihistamine treatment (prior to Dupixent).>6 weeks

    from chunk 127

    Bullous Pemphigoid - Initial Therapy

    Covered when criterion is met

    BP criteria: Initial: Approve for bullous pemphigoid as stated in the policy.

    from chunk 127

    Allergic Fungal Rhinosinusitis (AFRS) - Initial Therapy

    Covered when ALL of the following are met

    AFRS criteria: Patient has AFR confirmed by IgE-mediated inflammatory response to fungal hyphae confirmed by specific IgE serology or skin test AND nasal polyps confirmed by direct exam, endoscopy, or sinus CT AND signs characteristic of AFR on CT scan AND patient has had at least one prior sino-nasal surgery.prior sinonasal surgery required

    from chunk 127

    ESA/Anemia indications and thresholds

    Coverage for anemia-related indications (ESA/Actimmune context) with indication-specific criteria

    Anemia in CKD not on dialysis - Initial therapy: Approve if hemoglobin (Hb) < 10.0 g/dL for adults or <= 11 g/dL for children.Hb < 10.0 g/dL (adults); <= 11 g/dL (children)

    Continuation: if currently on ESA approve if Hb <= 12 g/dL

    Anemia due to chemotherapy - Initial therapy: Approve if patient is receiving myelosuppressive chemotherapy as non-curative treatment AND Hb < 10.0 g/dL.Hb < 10.0 g/dL

    Continuation if currently on ESA: Hb <= 12.0 g/dL

    Surgical patients to reduce RBC transfusions: Approve if Hb <= 13 AND surgery is elective, nonvascular and non-cardiac AND patient is unwilling or unable to donate autologous blood prior to surgery.Hb <= 13 g/dL

    Fabrazyme

    Fabrazyme coverage

    Fabrazyme diagnostic criteria: Approve if laboratory test demonstrates deficient alpha-galactosidase A activity in leukocytes or fibroblasts OR molecular genetic test demonstrates a pathogenic GLA gene variant.enzymatic deficiency or pathogenic GLA variant

    Prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist

    Selected other agents

    Other product-level indication highlights (fragmented)

    Erivedge - locally advanced BCC (new to therapy): Approve if patient has recurrent BCC following surgery or radiation OR is not a candidate for surgery and not a candidate for radiation.

    Coverage duration 1 year; age >=18

    Erlotinib - NSCLC EGFR mutation positive: Approve for advanced/metastatic NSCLC if EGFR mutation positive as detected by an approved test.EGFR mutation present

    Authorization 1 year; age >=18

    Fingolimod: Approve for relapsing forms of MS including clinically-isolated syndrome, relapsing-remitting, and active secondary progressive disease.Age >=10 years

    Prescribed by or in consultation with a neurologist or MS specialist; authorization 1 year

    Fingolimod (selected criteria)

    Covered when ALL of the following are met

    Fingolimod coverage criteria: 1) Diagnosis: relapsing form of MS (includes clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive). 2) Age: 10 years and older. 3) Prescriber: prescribed by or in consultation with a neurologist or an MS specialist. 4) Exclusion: concurrent use with other disease-modifying agents for MS is not allowed.

    Authorization will be for 1 year.

    Fintepla (Dravet and Lennox-Gastaut syndromes)

    Covered when ALL of the following are met

    Fintepla initial therapy (Dravet): 1) Diagnosis: Dravet syndrome. 2) Age: 2 years and older (initial therapy). 3) Prescriber: prescribed by or in consultation with a neurologist. 4) Prior therapy: patient has tried or is concomitantly receiving at least two other antiepileptic drugs OR has tried/is concomitantly receiving Epidiolex, Clobazam, or Diacomit.

    Authorization will be for 1 year.

    Fintepla continuation: 1) Patient is responding to therapy for Dravet or Lennox-Gastaut syndrome as applicable.

    Authorization will be for 1 year.

    Fotivda (renal cell carcinoma)

    Covered when ALL of the following are met

    Fotivda RCC: 1) Diagnosis: advanced, relapsed, or Stage IV renal cell carcinoma. 2) Prior therapy: patient has tried at least two other systemic regimens.

    Authorization will be for 1 year.

    Firmagon

    Covered when ALL of the following are met

    Firmagon: 1) Documentation of diagnosis. 2) Prescriber is or consulted with an oncologist. 3) Part B vs Part D determination will be made at time of prior authorization.

    Authorization duration noted elsewhere; prerequisite therapy required (documented as Yes).

    Gavreto (NSCLC, Differentiated Thyroid Cancer, Anaplastic/Medullary thyroid cancers)

    Covered when ALL of the following are met

    Gavreto NSCLC: 1) Diagnosis: advanced, recurrent, or metastatic NSCLC. 2) Tumor: RET fusion-positive disease detected by an FDA-approved test. 3) Age: NSCLC patients 18 years and older.

    Authorization will be for 1 year.

    Gavreto thyroid cancers: Differentiated thyroid cancer: unresectable, recurrent, or metastatic disease AND RET fusion-positive or RET-mutation-positive AND disease requires systemic therapy AND either (i) papillary/follicular carcinoma that is radioactive iodine-refractory OR (ii) oncocytic carcinoma. Anaplastic or medullary thyroid cancer: unresectable, recurrent, or metastatic disease with RET pathogenic variant.

    Authorization will be for 1 year.

    EGFR-targeted TKIs (Gefitinib, Gilotrif)

    Covered when ALL of the following are met

    Gefitinib: 1) Diagnosis: advanced or metastatic NSCLC. 2) Tumor: sensitizing EGFR mutation-positive NSCLC as detected by an approved test (examples: exon 19 deletions, exon 21 L858R, L861Q, G719X, S768I). 3) Age: 18 years and older.

    Authorization will be for 1 year; some off-label mutations listed.

    Gilotrif: 1) Diagnosis: advanced or metastatic NSCLC with sensitizing EGFR mutation-positive disease or NSCLC squamous cell type in certain settings. 2) Age: 18 years and older. 3) For metastatic squamous cell NSCLC patient must have disease progression after platinum based chemotherapy. 4) Head and neck cancer approvals require disease progression on or after platinum-based chemotherapy.

    Authorization will be for 1 year; Part B before Part D step therapy applies to MA-PD beneficiaries.

    Oncology and MS initial coverage criteria

    Covered when ALL of the following are met for the specified indications:

    EGFR-mutant advanced/metastatic NSCLC: Patient has advanced or metastatic non-small cell lung cancer with a sensitizing EGFR mutation detected by an approved test (examples: exon 19 deletions, exon 21 L858R, L861Q, G719X, S768I).

    Authorization will be for 1 year; applies to adults 18+ where age specified.

    Metastatic squamous NSCLC: Patient has metastatic squamous cell NSCLC and disease progression after treatment with platinum-based chemotherapy.

    Authorization will be for 1 year.

    Head and neck cancer (non-nasopharyngeal): Patient has non-nasopharyngeal head and neck cancer with disease progression on or after platinum-based chemotherapy.

    Approval stated; Part B before Part D step therapy applies only to MA-PD beneficiaries.

    Glatiramer for relapsing MS:

    General product coverage statements

    General coverage notes provided per product header:

    FDA-approved indications: Many product entries list 'All FDA-approved Indications' as covered or considered.

    Authorization durations commonly 1 year.

    Hernexeos - Covered with criteria

    Hernexeos

    Hernexeos general criteria: Required Medical Information: Diagnosis; Age restriction: 18 years and older; Coverage duration: 1 year; Indications: Non-small cell lung cancer - both (A and B): A) Unresectable or metastatic. All FDA-approved Indications.

    From chunk 199

    Hyrnuo - Covered with criteria

    Hyrnuo

    Hyrnuo general criteria: Required Medical Information: Diagnosis; Age restriction: 18 years and older; Coverage duration: 1 year; Prerequisite therapy required: Yes; Indications: All FDA-approved indications as specified.

    From chunk 217

    High-risk medications - Conditional coverage

    High-risk medications (group-level rules)

    High-risk medication baseline criteria: Age-based policy: patients <65 years: approve; patients >=65 years: additional criteria apply (prescriber must assess risk vs benefit); Prescriber must confirm risk/benefit assessment for initiation/continuation; Coverage duration typically 12 months; Prior prerequisite therapy required in many entries and specific alternative agents or trials are listed per drug.

    Examples include benztropine, clorazepate, cyproheptadine, hydroxyzine, phenobarbital, scopolamine, cyclobenzaprine, temazepam.

    Initial Authorization

    Covered when ALL of the following are met:

    Initial Authorization: 1) Patient is 18 years of age or older; 2) Required medical information includes diagnosis; 3) Prerequisite therapy has been tried as required; 4) Indication is an FDA-approved indication.

    Authorization will be for 1 year.

    Indication-specific approval criteria

    Covered when the following indication-specific requirements are met:

    Chronic Lymphocytic Leukemia (CLL): Approve for CLL per product criteria.

    From chunk 235

    Graft-versus-Host Disease (GVHD): Approve if patient is 1 year of age or older AND has tried one conventional systemic treatment for GVHD (examples: corticosteroids, imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib).age >= 1 year

    From chunk 235

    B-cell lymphoma: Approve if patient has tried at least one systemic regimen (examples listed).

    From chunk 235

    Primary CNS Lymphoma:

    Inrebic — Initial Authorization Criteria

    Inrebic — approve when ALL of the following are met:

    Inrebic Approval Conditions: Diagnosis documented; Age 18 years or older; Coverage duration 1 year; Indications: Myelofibrosis (including primary, post-PV, post-ET) — approve if higher-risk disease; Myeloid/lymphoid neoplasms with eosinophilia — approve if tumor has a JAK2 rearrangement; Accelerated or blast phase MPN — approve if patient has at least one disease-related symptom.

    From chunk 254

    Itovebi — Breast Cancer Criteria

    Itovebi — approve when ALL of the following are met:

    Itovebi Breast Cancer Criteria: Patient is postmenopausal or male, or is pre/perimenopausal plus receiving GnRH agonist or has bilateral oophorectomy/ovarian irradiation; Locally advanced or metastatic HR-positive disease; HER2-negative disease; PIK3CA-mutated breast cancer by approved test; Disease progression on adjuvant endocrine therapy or recurrence within 12 months of completing adjuvant endocrine therapy; Medication will be used in combination with palbociclib and fulvestrant.

    Coverage duration 1 year. From chunk 256

    Itraconazole — Indication-Specific Criteria

    Itraconazole (oral capsule) — approve when ALL of the following are met:

    Itraconazole Criteria: Requested drug will be used orally; For onychomycosis due to dermatophytes, the diagnosis has been confirmed by a fungal diagnostic test (KOH, fungal culture, or nail biopsy); For primary treatment of allergic bronchopulmonary aspergillosis, itraconazole initiated in combination with systemic corticosteroids.

    Coverage duration: 12 months for disseminated/CNS histo, histo/CM/CGD prophylaxis, chronic cavitary/necrotizing indications; Others: 6 months. From chunk 259

    Ivermectin — Indications

    Ivermectin (oral) — approve when the diagnosis matches listed indications and prerequisites are met:

    Ivermectin Indications: Pediculosis: approve if infection due to head, body, or pubic lice; Scabies: approve for classic scabies, treatment-resistant scabies, inability to tolerate topical treatment, crusted scabies, or for prevention/control — coverage duration 30 days.

    From chunk 261

    IVIG — Coverage

    IVIG — approve when medically accepted indications are documented:

    IVIG Authorization: Documented medically-accepted indication for IVIG; Coverage duration authorization will be for 12 months; Part B vs D determination per CMS may apply for PID in patient's home.

    From chunk 263

    Jakafi — Indication-Specific Criteria

    Jakafi/Jakafi XR — approve when indication-specific criteria are met:

    Jakafi General Criteria: Documented indication; Coverage duration 1 year; Age/indication-specific age limits apply (e.g., ALL 1–21 yrs; GVHD chronic >=12 yrs; other indications per segment); For polycythemia vera, trial of hydroxyurea or peginterferon alfa-2a or Besremi required; For chronic GVHD, tried one conventional systemic treatment; For acute GVHD, tried one systemic corticosteroid; For certain neoplasms, presence of JAK2 or CSF3R mutation required or concurrent therapies as specified.

    From chunks 268-269

    Jaypirca — Authorization

    Jaypirca — approve when:

    Jaypirca Criteria: Diagnosis documented; Prior authorization obtained; Coverage duration 1 year.

    From chunk 271

    This COVERAGE CRITERIA section defines the prior authorization conditions and indication‑specific requirements that must be met for approvals. For Actimmune (interferon gamma‑1b) the policy authorizes treatment for all FDA‑approved indications when the listed criteria are satisfied; typical authorization duration is 1 year. Initial approval for chronic granulomatous disease (CGD) requires documentation of the diagnosis by a molecular genetic test identifying a pathogenic variant linked to CGD, and the drug must be prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist (see required medical information).

    Initial approval for malignant osteopetrosis, severe requires radiographic (X‑ray) imaging demonstrating skeletal features consistent with the diagnosis, and therapy must be prescribed by or in consultation with an endocrinologist or hematologist. In all Actimmune indications the policy notes that prior authorization is required and that continuation approvals are issued when the patient shows a favorable clinical response; standard authorization duration where stated is 1 year.

    For the anti‑obesity drug class the policy specifically excludes concurrent coverage of >1 weight‑loss medication in this class. In addition, concurrent use of a GLP‑1 anti‑obesity agent (for example WEGOVY, SAXENDA, or ZEPBOUND) with a DPP‑4 inhibitor is listed as an exclusion. GLP‑1 initiation criteria require failure of the program’s specified preferred agents and meet age/BMI thresholds per the detailed anti‑obesity criteria; renewal requires documented weight‑loss or maintained BMI percentile as stated in the anti‑obesity criteria.

    Providers requesting authorization for an anti‑obesity GLP‑1 should therefore document that the patient has met the program’s prerequisite trials and is not receiving another weight‑loss medication in the same class or a DPP‑4 inhibitor concurrently, because such combinations are explicitly excluded from coverage.

    Arcalyst (IL‑1 blockade) contains an explicit exclusion: concurrent biologic therapy is not allowed. Initial therapy for deficiency of interleukin‑1 receptor antagonist (DIRA) additionally requires confirmed bi‑allelic pathogenic variants in the IL1RN gene and documentation of prior clinical benefit with anakinra subcutaneous injection before Arcalyst will be authorized.

    Age and prescriber restrictions for Arcalyst indications are specified: initial CAPS and pericarditis therapy require patients be ≥12 years of age and prescriptions must be by or in consultation with the specialty clinicians listed (for example rheumatologist, geneticist, allergist/immunologist, dermatologist; cardiologist for pericarditis). Continuation authorizations require documentation of a positive clinical response.

    The policy contains a general rule prohibiting concurrent biologic therapy for certain specialty agents. For Arcalyst this is an explicit exclusion; similarly, other entries (for example Benlysta) also exclude concurrent use with other biologics. Requests that propose overlapping biologic therapies should include documentation supporting a clinical rationale and will be denied if they contravene the product‑specific exclusion.

    When a requested agent’s criteria list concurrent biologic therapy as an exclusion, the prior authorization must demonstrate the patient is not receiving another biologic (or, where the policy allows, document why the concurrent agent is being stopped and why overlap is clinically necessary). Failure to meet the concurrent‑therapy exclusion is a common denial risk.

    Relevant Codes and Clinical Thresholds

    Listed drug products without explicit codesmixed
    BENZPHETAMINE HCL 50 MG TABLETBENZPHETAMINE HCL 50 MG TABLET (Rx)
    DIETHYLPROPION 25 MG TABLETDIETHYLPROPION 25 MG TABLET
    DIETHYLPROPION ER 75 MG TABLETDIETHYLPROPION ER 75 MG TABLET
    LIRAGLUTIDE 5-PAK 18 MG/3 MLLIRAGLUTIDE 5-PAK 18 MG/3 ML OUTER
    LOMAIRA 8 MG TABLETLOMAIRA 8 MG TABLET
    ORLISTAT 120 MG CAPSULEORLISTAT 120 MG CAPSULE
    PHENDIMETRAZINE 35 MG TABLETPHENDIMETRAZINE 35 MG TABLET
    PHENDIMETRAZINE ER 105 MG CAPPHENDIMETRAZINE ER 105 MG CAP
    PHENTERMINE 15 MG CAPSULEPHENTERMINE 15 MG CAPSULE
    PHENTERMINE 30 MG CAPSULEPHENTERMINE 30 MG CAPSULE
    1–10 of 26
    1/3
    IV antifungalsneutralCovered
    voriconazole (intravenous)voriconazole intravenous recon soln
    voriconazole-HPBCDvoriconazole-HPBCD
    IV antifungals - additional specified product (voriconazole intravenous)mixedCovered
    voriconazole (intravenous)voriconazole intravenous recon soln; coverage duration 3 months
    Alpha 1 proteinase inhibitorsneutralCovered
    Prolastin-CProlastin-C intravenous solution
    AlosetronneutralCovered
    alosetronalosetron; age restriction: 18 years and older; coverage duration: 12 months
    Arcalyst (IL-1 blockade)neutralCovered
    ArcalystArcalyst; exclusion: concurrent biologic therapy; age restrictions: initial therapy CAPS/Pericarditis >= 12 years; coverage duration: CAPS initial 3 months (1 yr cont), DIRA initial 6 months (1 yr cont), Pericarditis initial 3 months (1 yr cont)
    inv-99: Plasma ammonia
    Plasma ammonia threshold>= 50 micromol/L (required for acute hyperammonemia in PA/MMA)
    Indication contextUsed to support approval of carglumic acid for N‑acetylglutamate synthase deficiency or acute hyperammonemia in PA/MMA
    Documentation requiredDiagnosis and relevant laboratory results (plasma ammonia) must be provided
    inv-100: Functional C1-INH level
    Functional C1-INH level threshold< 50% of normal (baseline) for HAE Type I/II confirmation
    Additional lab requirement

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior authorization required

    Prior authorization is required for Actimmune; approve for 1 year if diagnostic criteria are met and prescriber restrictions are satisfied (e.g., CGD prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist; malignant osteopetrosis prescribed by or in consultation with an endocrinologist or hematologist).

    Prior Authorization

    PA required for specialty agents with indication evidence

    Prior authorization is required for listed specialty agents and will be granted only when indication-specific evidence is provided (for example, ALK-positive status for ALK-targeted agents and required prior therapy trials where noted).

    Prior Authorization

    PA required for Actimmune/Arcalyst

    Prior authorization is required for Actimmune and Arcalyst product lines with defined initial and continuation criteria including age and prescriber restrictions (e.g., DIRA requires confirmed bi-allelic IL1RN pathogenic variants and clinical benefit with anakinra; CAPS/pericarditis age and specialist requirements).

    Definitions and Diagnostic Criteria

    inv-214: Chronic granulomatous disease (CGD)
    DefinitionChronic granulomatous disease (CGD): a primary immunodeficiency disorder requiring molecular genetic test identifying a pathogenic variant linked to CGD for approval
    Diagnostic evidenceMolecular genetic test result documenting gene-related pathogenic variant must be in the medical record
    Prescriber requirementPrescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist
    inv-215: Malignant osteopetrosis, severe
    DefinitionMalignant osteopetrosis, severe: a severe bone disorder requiring radiographic (X-ray) imaging demonstrating skeletal features for approval
    Diagnostic evidenceRadiographic imaging demonstrating characteristic skeletal features must be documented

    Background and Policy Scope

    Actimmune (interferon gamma‑1b) is included in the Meridian Health Plan of Michigan prior authorization program. Covered indications include all FDA‑approved indications, with indication‑specific diagnostic confirmation and prescriber requirements. For example, approval for chronic granulomatous disease (CGD) requires documentation of a molecular genetic test identifying a pathogenic variant linked to CGD and the drug must be prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist. Approval for malignant osteopetrosis, severe requires radiographic (X‑ray) evidence demonstrating skeletal features consistent with the diagnosis and prescriber involvement by an endocrinologist or hematologist. Where noted, authorization durations default to 1 year, and some related products (e.g., Arcalyst) have shorter initial authorization windows for specific indications with defined continuation criteria.

    Policy Summary
    Payermeridian_health_plan_of_michigan
    PolicyActimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document diagnostic confirmation (molecular genetic test for CGD or radiographic evidence for malignant osteopetrosis) to support a 1-year approval.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RequirementsRelevant Codes and Clinical ThresholdsPrior Authorization, Documentation, and Step TherapyDefinitions and Diagnostic CriteriaBackground and Policy Scope
    For renewal provide documentation of maintained/improved BMI percentile (12-17) or >=5% weight loss from baseline (18+) at therapy initiation; first renewals approved before 2026 require additional attestations.

    from chunks 33 and 34

    GIST: Approve if patient has tried two of the following: imatinib, Ayvakit, sunitinib, dasatinib, Stivarga, or Qinlock.

    chunk 78

    NSCLC with RET rearrangement: Approve if tumor is RET rearrangement positive AND progressed on one of first-line therapies Gavreto or Retevmo.

    chunk 78

    Neuroendocrine tumors: Approve if (A) locally advanced, unresectable, or metastatic disease AND (B) well-differentiated neuroendocrine tumors AND (C) pancreatic or extra-pancreatic AND (D) used as subsequent therapy.

    chunk 78

    elective, nonvascular, non-cardiac surgery; autologous donation not possible or patient unwilling

    MDS - Initial therapy: Approve if Hb < 10 g/dL OR serum erythropoietin <= 500 mU/mL.Hb < 10 g/dL or EPO <= 500 mU/mL

    Continuation if on ESA: Hb <= 12.0 g/dL

    Myelofibrosis - Initial therapy: Approve if Hb < 10 g/dL OR serum erythropoietin <= 500 mU/mL.Hb < 10 g/dL or EPO <= 500 mU/mL

    Continuation if on ESA: Hb <= 12.0 g/dL

    HIV with zidovudine - Initial therapy: Approve if Hb < 10.0 g/dL OR serum erythropoietin <= 500 mU/mL.Hb < 10.0 g/dL or EPO <= 500 mU/mL

    Continuation if on ESA: Hb <= 12.0 g/dL

    Patient has a relapsing form of multiple sclerosis (clinically-isolated syndrome, relapsing-remitting, or active secondary progressive) and therapy is prescribed by or after consultation with a neurologist or MS specialist.

    Authorization will be for 1 year.

    Approve if patient is not a candidate for or is intolerant to high-dose methotrexate OR has tried at least one therapy (examples listed).

    From chunk 235

    Hairy Cell Leukemia: Approve if patient has tried at least two systemic regimens.

    From chunk 235

    General: All FDA-approved indications and some medically-accepted indications are included. Coverage duration is 1 year. Age restriction for most non-GVHD indications is 18 years and older.age >= 18 years for most indications

    From chunk 235

    Baseline low serum C4 level required alongside functional C1‑INH
    Prescriber requirementPrescribed by or in consultation with an allergist/immunologist or HAE specialist
    inv-101: blood eosinophil (asthma)
    Asthma blood eosinophil threshold>= 150 cells per microliter within the previous 6 weeks (or prior to Dupixent/another monoclonal antibody)
    Controller therapy requirementPatient must have used an inhaled corticosteroid plus at least one additional asthma controller/maintenance medication
    Uncontrolled asthma definition examples>=2 oral corticosteroid exacerbations in past year, OR >=1 hospitalization/ED visit, OR FEV1 <80% predicted, OR FEV1/FVC <0.8
    inv-102: blood eosinophil (COPD)
    COPD blood eosinophil threshold>= 300 cells per microliter within the previous 6 weeks (or prior to Dupixent/another monoclonal antibody)
    Prior therapy requirementReceived at least 3 months of combination therapy with at least two of LAMA, LABA, or ICS
    Exacerbation history requirementEither >=2 exacerbations in prior 12 months requiring systemic corticosteroids or >=1 exacerbation requiring hospitalization
    inv-103: EoE biopsy threshold
    EoE biopsy threshold>= 15 intraepithelial eosinophils per high‑power field on endoscopic biopsy
    Other requirementsPatient weighs >=15 kg and received an Rx‑strength PPI for at least 8 weeks; exclude secondary causes of EoE
    DocumentationEndoscopic biopsy report and PPI trial documentation required
    inv-104: CRSwNP oral corticosteroid history
    Oral corticosteroid history for CRSwNPReceived oral corticosteroids for at least 5 days in the last 2 years (unless contraindicated) OR prior surgery for nasal polyps
    Symptom duration/confirmationPresence of >=2 CRSwNP symptoms for 8 weeks and diagnosis confirmed by direct exam, endoscopy, or sinus CT
    Concurrent therapyConcurrent use with nasal corticosteroid required
    inv-105: Prurigo nodularis duration
    Prurigo nodularis durationPruritus lasting at least 6 weeks
    Indication evidenceDocument duration of pruritus and prior therapies as applicable
    Coverage timingInitial therapy criteria reference: 6‑week symptom duration
    inv-106: CSU duration
    CSU duration requirementUrticaria for greater than 6 weeks despite non‑sedating H1 antihistamine treatment
    Prior therapy contextDocument trial of non‑sedating H1 antihistamines before biologic therapy (e.g., prior to Dupixent)
    Documentation neededClinical notes documenting symptom duration and antihistamine use
    inv-107: Hemoglobin thresholds
    Hemoglobin thresholds (general)Initial therapy: Hb < 10.0 g/dL for adults (varies by indication); Continuation on ESA: Hb <= 12.0 g/dL
    Surgical patients thresholdFor elective nonvascular/noncardiac surgery to reduce RBC transfusions: Hb <= 13 g/dL
    Pediatric/other variationsSome indications (children) use Hb <= 11 g/dL for initial therapy — follow indication‑specific criteria
    inv-108: Serum erythropoietin
    Serum erythropoietin threshold<= 500 mU/mL for initial therapy in MDS, myelofibrosis, or HIV zidovudine‑related anemia
    Use with Hb criteriaEPO threshold is considered alongside hemoglobin thresholds for ESA initiation
    Documentation requiredProvide serum erythropoietin laboratory result when applicable
    inv-109: Age (fingolimod)
    Minimum age for fingolimod>= 10 years
    Indication contextFor relapsing forms of multiple sclerosis (including clinically‑isolated syndrome, relapsing‑remitting, active secondary progressive)
    Prescriber requirementPrescribed by or in consultation with a neurologist or MS specialist
    inv-110: Authorization duration
    Typical authorization durationAuthorization will be for 1 year where stated
    Exceptions notedSome single‑use or short acute courses (e.g., carglumic acid without genetic test) may have shorter durations per indication
    Provider actionPA requests should document indication, required labs/tests, and prescriber specialty to support a 1‑year authorization
    Prior Authorization

    Arikayce prior authorization and documentation

    Arikayce requires prior authorization for MAC lung disease; initial therapy is limited to patients 18 years and older and documentation must include diagnosis, prior medication history, and positive sputum culture for MAC with amikacin susceptibility where applicable.

    Prior Authorization

    Besremi (Actimmune) PA requirement

    Besremi (Actimmune) requires prior authorization; requests must document diagnosis, the prescriber must be an oncologist or hematologist (or consult), patients must be 18 years or older, and approvals are for 1 year.

    Prior Authorization

    Betaseron PA and prescriber restriction

    Betaseron requires prior authorization; prescriber or consultation with a neurologist or MS specialist is required and authorization is for 1 year; concurrent use with other disease-modifying MS agents is an exclusion.

    Prior Authorization

    Brinsupri PA requirement

    Brinsupri for non‑CF bronchiectasis requires prior authorization with documentation of chest CT–confirmed bronchiectasis, exacerbation history per age group, pulmonologist or ID prescriber involvement, and is authorized for 1 year.

    Prior Authorization

    Haegarda PA and lab confirmation

    Haegarda requires prior authorization for prophylaxis of HAE due to C1‑INH deficiency; baseline labs documenting functional C1‑INH <50% of normal and low serum C4 (or genetic/family-history criteria for HAE with normal C1‑INH) and a prescribing specialist are required; authorizations typically for 1 year.

    Prior Authorization

    Cabometyx prior authorization

    Cabometyx requires prior authorization with indication-specific documentation (diagnosis, histology, RET rearrangement status where applicable), applicable age restrictions, prior therapy requirements, and typical authorization of 1 year.

    Prior Authorization

    Calquence PA and prerequisite therapy

    Calquence requires prior authorization; coverage is typically for 1 year and prerequisite systemic therapy is required for certain indications (e.g., mantle cell lymphoma).

    Prior Authorization

    Prior authorization criteria (OCD/Panic/Autistic or Depression)

    Prior authorization for clomipramine is required; approve only if either (A) prescribed for OCD, panic disorder, or autistic disorder with prior inadequate response/intolerance/contraindication to an SNRI or SSRI, OR (B) prescribed for depression with prior inadequate response/intolerance/contraindication to two of SNRIs, SSRIs, mirtazapine, or bupropion.

    Prior Authorization

    PA requirement for dalfampridine (MS)

    Dalfampridine (for MS) requires prior authorization; initial and continuation approvals are for 1 year and requests must document the patient is ambulatory, that dalfampridine is being used to improve or maintain mobility, objective impaired ambulation (e.g., timed 25‑foot walk or MSWS‑12), and neurologist/MS specialist involvement.

    Prior Authorization

    PA plus prescriber and prerequisite therapy requirements

    Many products require prior authorization and have prescriber restrictions; prerequisite therapy is often required and many indications demand the drug be prescribed by or after consultation with a relevant specialist (examples cited across indications).

    Prior Authorization

    PA with lab thresholds and prescriber restrictions

    Some prior authorizations include explicit laboratory and prescriber requirements (for example, ESA/anaemia approvals require hemoglobin and, when applicable, serum erythropoietin thresholds; certain indications require hematologist/oncologist involvement).

    Prior Authorization

    Fabrazyme prior authorization and diagnostic confirmation

    Fabrazyme requires prior authorization with genetic or laboratory confirmation of deficient alpha‑galactosidase A activity (or pathogenic GLA variant) and must be prescribed by or in consultation with an appropriate specialist; authorization is for 1 year.

    Prior Authorization

    Fingolimod PA and required prescriber/age

    Fingolimod requires prior authorization; requests must document diagnosis of a relapsing form of MS, prescriber involvement of a neurologist or MS specialist, patient age 10 years or older, and authorizations are for 1 year.

    Prior Authorization

    Fintepla PA and age/prior therapy

    Fintepla requires prior authorization; initial therapy has an age restriction (2 years and older for Dravet) and prescriber restriction (neurologist consulted), prior/concomitant AED trial requirements for Dravet, and approvals are for 1 year.

    Prior Authorization

    Firmagon PA and billing determination

    Firmagon requires prior authorization; prescriber must be or consult with an oncologist and a Part B vs Part D determination will be made at the time of PA; authorization duration is noted as 1 year in other sections.

    Prior Authorization

    EGFR-targeted TKIs prior authorization and mutation documentation

    EGFR‑targeted TKIs (e.g., gefitinib, afatinib/Gilotrif) require prior authorization; approvals require documented sensitizing EGFR mutation by an approved test, age 18+, and are typically authorized for 1 year.

    Prior Authorization

    Oncology prior authorization and mutation proof

    Prior authorization is required for listed oncology indications; for EGFR‑mutant advanced/metastatic NSCLC approval requires documented sensitizing EGFR mutation and is authorized for 1 year.

    Prior Authorization

    Glatiramer PA and prescriber requirement

    Glatiramer products require prior authorization; approval is for 1 year and the prescriber should be or consult with a neurologist or MS specialist; concurrent use with other disease‑modifying MS agents is excluded.

    Prior Authorization

    Hernexeos PA and age requirement

    Hernexeos requires prior authorization; documentation of diagnosis is required, patient must be 18 years or older, and authorization is for 1 year.

    Prior Authorization

    Hyrnuo PA, age and prerequisite therapy

    Hyrnuo requires prior authorization; diagnosis must be provided, patient must be 18 years or older, authorization is for 1 year, and prerequisite therapy is required where specified.

    Prior Authorization

    High‑risk medications PA and age‑based rules

    Multiple high‑risk medications require prior authorization with age‑based rules: patients <65 years generally approve; patients ≥65 years require additional criteria and prescriber risk‑benefit assessment documentation; coverage duration typically 12 months.

    Prior Authorization

    PA required — typical 1‑year authorization

    Prior authorization is required for many products; where stated, authorizations are for 1 year and apply to patients 18 years and older unless otherwise specified.

    Prior Authorization

    PA and prerequisite therapy where specified

    Prior authorization is required and prerequisite therapy is required for some indications; see product‑specific criteria for required prior regimens.

    Prior Authorization

    Inrebic prior authorization and age/diagnosis

    Inrebic requires prior authorization; requests must document diagnosis, patient age ≥18 years, and approvals are for 1 year with indication‑specific criteria (e.g., higher‑risk myelofibrosis).

    Prior Authorization

    Itovebi PA and breast cancer criteria

    Itovebi requires prior authorization with breast cancer–specific documentation (postmenopausal status or ovarian suppression, HR‑positive/HER2‑negative disease, PIK3CA mutation by approved test, prior endocrine therapy progression/recurrence within 12 months) and is authorized for 1 year.

    Prior Authorization

    Itraconazole PA and diagnostic documentation

    Itraconazole (oral capsule) requires prior authorization; documentation must confirm intended oral use and diagnostic confirmation for onychomycosis (e.g., KOH, fungal culture, or nail biopsy); duration varies by indication (6 or 12 months).

    Prior Authorization

    Ivermectin PA and duration

    Ivermectin (oral) requires prior authorization; coverage duration is 30 days and prerequisite therapy is required for some indications (per product criteria).

    Prior Authorization

    IVIG PA and authorization duration

    IVIG (Gamunex‑C) requires prior authorization for medically accepted indications; authorizations are issued for 12 months and Part B vs D determination may apply per CMS guidance.

    Prior Authorization

    Jakafi PA and step therapy

    Jakafi/Jakafi XR requires prior authorization; coverage is for 1 year and specific prerequisite therapies are required for indications (e.g., hydroxyurea or peginterferon for polycythemia vera; conventional systemic treatment for chronic GVHD).

    Prior Authorization

    Jaypirca prior authorization

    Jaypirca requires prior authorization with documentation of diagnosis; coverage is for 1 year per the policy excerpt.

    Step Therapy

    No prerequisite therapy required when stated

    No prerequisite therapy required for some products; where the policy states 'No' for prerequisite therapy, no prior trials are required for initial approval.

    Step Therapy

    Step therapy requirements and prior trial documentation

    Some products require step therapy: providers must document prior trials of specified agents (for example, Alunbrig requires trial of Alecensa, Ensacove, or Lorbrena for NSCLC patients new to therapy; GLP‑1 anti‑obesity agents require failure of five preferred agents unless exceptions apply).

    Step Therapy

    Benlysta concurrent therapy requirement

    Benlysta for SLE must be used concurrently with at least one other standard therapy unless the patient is intolerant; continuation approvals require documented response while on concurrent therapy.

    Step Therapy

    Bosentan step/sequence requirement

    For CTEPH use of bosentan, the patient must have tried Adempas, have a contraindication to Adempas, or be currently receiving bosentan before approval is granted.

    Step Therapy

    Brukinsa prerequisite therapy

    Brukinsa for follicular lymphoma requires prior trial of at least two other systemic regimens before approval in combination with obinutuzumab.

    Step Therapy

    Clobazam step therapy requirements

    Clobazam initial therapy for Lennox‑Gastaut requires that the patient has tried or is concomitantly receiving one of specified AEDs; treatment‑refractory seizures require trial of at least two other antiepileptic drugs.

    Step Therapy

    Step therapy is required where indicated

    Yes — step therapy (prerequisite therapy) is required for many products as specified in the prior authorization criteria; providers must document trials, intolerances, or contraindications to required prior therapies.

    Step Therapy

    No prerequisite therapy for specified products

    No prerequisite therapy required for certain products where the policy explicitly states 'No' for prerequisite therapy (these requests still require PA and other documentation as noted).

    Step Therapy

    Prerequisite/concomitant therapy requirements (immunology/respiratory)

    Many immunology and respiratory indications require prerequisite or concomitant therapy documentation (for example, asthma requires prior use of inhaled corticosteroid plus another controller; CRSwNP requires prior oral corticosteroid use or prior surgery).

    Step Therapy

    Prerequisite therapy required for selected indications

    Some indications require product‑specific prerequisite therapy trials as listed in the criteria (examples include everolimus and other oncology agents where prior systemic regimens are required).

    Step Therapy

    Fintepla step therapy for Dravet syndrome

    Fintepla for Dravet syndrome requires that the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or has tried/is receiving Epidiolex, Clobazam, or Diacomit prior to approval.

    Step Therapy

    Fotivda step therapy for RCC

    Fotivda for renal cell carcinoma initial approval requires prior use of at least two other systemic regimens (patient must have relapsed or Stage IV disease).

    Step Therapy

    Fruzaqla prerequisite chemotherapy sequence

    Fruzaqla (fragment) requires prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and an anti‑VEGF agent for colorectal/appendiceal cancer per the detailed criteria.

    Step Therapy

    Platinum chemotherapy prerequisite (squamous NSCLC)

    For metastatic squamous NSCLC approvals, disease progression after platinum‑based chemotherapy is required prior to approval.

    Step Therapy

    Head and neck platinum progression requirement

    Head and neck cancer approvals require disease progression on or after platinum‑based chemotherapy as a prerequisite for coverage.

    Step Therapy

    Prerequisite therapy / alternatives for high‑risk meds

    Many high‑risk medications require trials or intolerance to specified alternative (non‑HRM) agents before approval (for example, hydroxyzine requires trials of specified non‑HRM alternatives for rhinitis).

    Step Therapy

    Prerequisite therapy required where indicated

    Prerequisite therapy is required prior to approval for products where the policy indicates 'Prerequisite Therapy Required = Yes'; providers must document trials or contraindications as specified.

    Step Therapy

    Prerequisite systemic therapies required per indication

    Step therapy/prerequisite systemic treatments are required for certain indications; providers must follow the indication‑specific step sequences listed in the clinical criteria.

    Step Therapy

    Jakafi step therapy (polycythemia vera)

    For Jakafi in polycythemia vera, patients must have tried hydroxyurea or peginterferon alfa‑2a or Besremi prior to approval.

    Step Therapy

    Jakafi step therapy (essential thrombocythemia)

    For Jakafi in essential thrombocythemia, a trial of hydroxyurea, peginterferon alfa‑2a, or anagrelide is required before Jakafi will be approved.

    Documentation Required

    Required diagnostic documentation (CGD, osteopetrosis)

    Providers must submit required diagnostic documentation: medical record must document the diagnosis; for CGD provide a molecular genetic test identifying a pathogenic variant; for malignant osteopetrosis provide radiographic (X‑ray) imaging demonstrating related skeletal features.

    Documentation Required

    Required documentation and confirmatory testing

    Provide diagnosis and confirmatory testing results where applicable (examples: right‑heart catheterization results for PAH; ALK status for ALK‑targeted therapies; IL1RN bi‑allelic pathogenic variants for DIRA).

    Documentation Required

    Required medical information including genetic confirmation

    Required medical information must include diagnosis and, when applicable, genetic confirmation (e.g., confirmed bi‑allelic IL1RN pathogenic variants for DIRA) and documentation of prior response to therapy (e.g., clinical benefit with anakinra for DIRA).

    Documentation Required

    Arikayce required documentation (MAC culture & susceptibility)

    For Arikayce, documentation must include diagnosis, prior medication history, and a positive sputum culture for MAC with documentation of amikacin susceptibility when indicated.

    Documentation Required

    Right‑heart catheterization documentation (PAH)

    Right‑heart catheterization results are required to confirm pulmonary arterial hypertension (WHO Group 1) when documenting bosentan therapy.

    Documentation Required

    Mutation test documentation required

    Mutation status must be documented where required (for example, BRAF V600 mutation status for Braftovi).

    Documentation Required

    Haegarda required baseline labs and continuation evidence

    For Haegarda, document baseline functional C1‑INH level (<50% of normal) and low serum C4 for HAE Type I/II prophylaxis; for continuation include prescriber statement of favorable clinical response.

    Documentation Required

    Cabometyx required documentation (diagnosis, RET status)

    For Cabometyx, include diagnosis, histology, RET gene rearrangement status for NSCLC where applicable, and prior therapies per the indication requested.

    Documentation Required

    Carglumic acid documentation (genetics or plasma ammonia)

    For carglumic acid, provide genetic test results confirming N‑acetylglutamate synthase deficiency or plasma ammonia level ≥50 micromol/L for acute treatment indications.

    Documentation Required

    Required documentation for psychiatric indications

    Required documentation for psychiatric and related indications must include diagnosis and prior treatment failures/intolerance/contraindications to specified classes (e.g., SSRIs/SNRIs for OCD/panic/autistic disorder or two of SNRI/SSRI/mirtazapine/bupropion for depression).

    Documentation Required

    Dalfampridine documentation (ambulatory status and objective measure)

    For dalfampridine, documentation must show diagnosis of MS, that the patient is ambulatory, the drug is intended to improve or maintain mobility, and objective impaired ambulation measured by timed 25‑foot walk or MSWS‑12.

    Documentation Required

    Documentation for immunology/respiratory indications

    Provide diagnosis, relevant objective tests (e.g., blood eosinophil counts, endoscopic biopsy results, CT/endoscopy for nasal polyps), prior therapy trials and dates, and prescriber specialty/consultation for the immunology/respiratory indications.

    Documentation Required

    Fabrazyme diagnostic documentation and specialist prescriber

    Fabrazyme requests must include diagnosis and genetic/laboratory test results demonstrating deficient alpha‑galactosidase A activity in leukocytes or fibroblasts or a pathogenic GLA gene variant, plus specialist prescriber involvement.

    Documentation Required

    ESA anemia lab documentation required

    ESA anemia approvals require hemoglobin values consistent with the indication (e.g., Hb <10.0 g/dL for many initial therapies) and, when applicable, serum erythropoietin levels (≤500 mU/mL for certain indications).

    Documentation Required

    Fingolimod required medical information

    For fingolimod, required medical information includes diagnosis of a relapsing form of MS (including clinically‑isolated syndrome, relapsing‑remitting, or active secondary progressive) and prescriber specialty involvement.

    Documentation Required

    Fintepla required documentation of prior/concomitant AEDs

    Fintepla prior authorization requests must include diagnosis and documentation of prior or concomitant antiepileptic therapies for Dravet syndrome when applicable.

    Documentation Required

    Firmagon required documentation and billing note

    Firmagon prior authorization requires documentation of diagnosis and that the prescriber is or consulted with an oncologist; billing (Part B vs Part D) will be determined at time of PA.

    Documentation Required

    Gavreto required mutation testing documentation

    Gavreto requests must include diagnosis and RET fusion or mutation testing results where applicable for NSCLC and thyroid cancer indications.

    Documentation Required

    EGFR mutation test documentation required

    Documentation of a sensitizing EGFR mutation by an approved test (examples include exon 19 deletions, exon 21 L858R, L861Q, G719X, S768I) is required for EGFR‑positive NSCLC approvals.

    Documentation Required

    Glatiramer MS documentation and prescriber requirement

    For glatiramer products, document that the diagnosis is a relapsing form of MS and that the prescriber is a neurologist or MS specialist (or consulted) for prior authorization.

    Documentation Required

    Hernexeos/Hyrnuo required diagnosis documentation

    Provide diagnosis as required medical information for Hernexeos and Hyrnuo prior authorization requests; include other indication‑specific documentation as applicable.

    Documentation Required

    Required documentation of prior systemic therapies

    Prior authorization requests must include diagnosis and evidence of prior systemic therapies tried as specified by indication (examples shown in the product criteria).

    Documentation Required

    Itraconazole documentation for onychomycosis

    For oral itraconazole, documentation should include the intended oral route and fungal diagnostic confirmation for onychomycosis (e.g., KOH, fungal culture, or nail biopsy).

    Documentation Required

    Itovebi required breast‑cancer documentation

    Itovebi requests must include menopausal status or concurrent GnRH agonist use, HR/HER2/PIK3CA status, prior endocrine therapy history, and planned combination with palbociclib and fulvestrant where applicable.

    Documentation Required

    Jakafi prior therapy documentation

    Jakafi prior authorization must document prior therapies where specified (for example, hydroxyurea or peginterferon for PV; prior systemic treatment for chronic GVHD).

    Note
    Denial Risk

    Diagnostic confirmation required — denial risk

    Diagnostic confirmation is required where stated; lack of required diagnostic confirmation (e.g., molecular genetic test for CGD or radiographic evidence for malignant osteopetrosis) may trigger denial.

    Denial Risk

    Anti‑obesity agent exclusions may cause denial

    Concurrent use of more than one weight‑loss medication in the anti‑obesity drug class or combining a GLP‑1 anti‑obesity agent with a DPP‑4 inhibitor may trigger exclusion/denial for anti‑obesity agents.

    Denial Risk

    Concurrent biologic therapy exclusion

    Concurrent biologic therapy is listed as an exclusion for some products (for example, Arcalyst); concurrent biologic use may result in denial.

    Denial Risk

    Benlysta concurrent biologic exclusion

    Concurrent use of Benlysta with another biologic or Lupkynis is an exclusion; requests documenting concurrent biologic therapy risk denial.

    Denial Risk

    Age restriction noncompliance may trigger denial

    Requests risk denial if the patient is under age limits specified by the product (for example, many products require patients be 18 years or older).

    Denial Risk

    Prescriber restriction noncompliance — denial risk

    Denials may occur if required specialist prescriber involvement or consultation is not documented (examples: neurologist for Betaseron; cardiologist/pulmonologist for bosentan).

    Denial Risk

    HAE diagnostic confirmation required for Haegarda

    Lack of documentation confirming HAE Type I/II (functional C1‑INH <50% and low serum C4) at baseline may trigger denial for Haegarda prophylaxis.

    Denial Risk

    Cayston culture requirement — denial risk

    Absence of a Pseudomonas aeruginosa positive airway culture may result in denial for Cayston requests.

    Denial Risk

    Lack of prerequisite therapy — denial risk

    Requests that do not document trials, inadequate response, intolerance, or contraindication to required prior therapies risk denial (e.g., SSRIs/SNRIs for OCD/panic/autistic disorder or required oncology prior regimens).

    Denial Risk

    Ambulatory status/objective measures missing — denial trigger

    Requests may be denied if the patient is not ambulatory, the medication is not being used to improve or maintain mobility in MS, or no objective measure of impaired ambulation is provided (e.g., timed 25‑foot walk, MSWS‑12).

    Denial Risk

    Failure to meet indication criteria — denial risk

    Failure to meet indication‑specific criteria (for example, blood eosinophil thresholds for asthma/COPD, biopsy/PPI trial for EoE, prior therapies for CRSwNP/CSU/PN) may trigger denial for those indications.

    Denial Risk

    Medicare Part D dialysis denial for ESA in dialysis

    Anemia in patients with chronic renal failure on dialysis is denied under Medicare Part D; such claims should be submitted under the ESRD bundled payment benefit instead.

    Denial Risk

    Fingolimod concurrent‑agent exclusion — denial risk

    Concurrent use of fingolimod with other disease‑modifying MS agents is an exclusion and may trigger denial if documented.

    Denial Risk

    Fintepla prerequisite therapy — denial risk

    Fintepla initial approval for Dravet syndrome requires prior or concomitant trials of at least two other antiepileptic drugs or prior/concomitant Epidiolex, Clobazam, or Diacomit; absence of these prior therapies may risk denial.

    Denial Risk

    Fotivda prerequisite therapy — denial risk

    Fotivda for RCC requires relapsed or Stage IV disease and prior use of at least two other systemic regimens; lack of required prior therapies may trigger denial.

    Denial Risk

    NSCLC squamous cell progression — denial trigger

    For metastatic squamous NSCLC, lack of documentation of prior platinum‑based chemotherapy and disease progression may lead to non‑approval.

    Denial Risk

    NSCLC unresectable/metastatic documentation — denial risk

    For non‑small cell lung cancer with an activating mutation, absence of documentation that disease is unresectable or metastatic may trigger denial.

    Note
    Note
    Note
    Note
    Note
    Denial Risk

    Itraconazole diagnostic confirmation — denial risk

    Itraconazole for onychomycosis requires fungal diagnostic test confirmation; lack of diagnostic confirmation (KOH, culture, or biopsy) may lead to denial.

    Prescriber requirementPrescribed by or in consultation with an endocrinologist or hematologist
    inv-216: DIRA
    DefinitionDIRA: Deficiency of interleukin-1 receptor antagonist — initial therapy requires confirmed bi-allelic pathogenic variants in IL1RN
    Prior therapy evidenceClinical benefit with anakinra subcutaneous injection required for DIRA initial approval
    Prescriber requirementPrescribed by or in consultation with rheumatologist, geneticist, dermatologist, or specialist in autoinflammatory disorders
    inv-217: ALK-positive
    DefinitionALK-positive: disease with anaplastic lymphoma kinase rearrangement/fusion detected by an approved test required for ALK-targeted agent eligibility
    Documentation requiredALK status from an approved test must be provided in medical record
    Typical age restrictionMany ALK indications apply to patients 18 years and older unless otherwise specified
    inv-218: Deficiency of interleukin-1 receptor antagonist (DIRA)
    DefinitionDeficiency of interleukin-1 receptor antagonist (DIRA): requires confirmed bi-allelic pathogenic IL1RN variants and prior clinical benefit with anakinra for initial Arcalyst approval
    Continuation requirementContinuation approvals require documented positive response to therapy
    Prescriber requirementInitial DIRA therapy prescribed by specialized physicians as listed (rheum, geneticist, derm, or autoinflammatory disorder specialist)
    inv-219: Mycobacterium avium complex (MAC) lung disease
    DefinitionMycobacterium avium complex (MAC) lung disease: initial Arikayce therapy requires positive sputum culture for MAC with isolate susceptible to amikacin
    Treatment contextArikayce must be used in combination with a background multidrug regimen (eg, macrolide, ethambutol, rifamycin)
    Age/prescriberInitial MAC therapy limited to patients 18 years and older and prescribed by pulmonologist, infectious disease or MAC specialist
    inv-220: Autoantibody-positive systemic lupus erythematosus (SLE)
    DefinitionAutoantibody-positive SLE: positive ANA and/or anti-dsDNA; Benlysta must be used concurrently with at least one other standard therapy unless intolerant
    Documentation requiredDiagnosis and concurrent immunosuppressive regimen documented (eg, hydroxychloroquine, corticosteroid, mycophenolate)
    Prescriber requirementPrescribed by or in consultation with a rheumatologist or relevant specialist
    inv-221: Pulmonary arterial hypertension (PAH) WHO Group 1
    DefinitionPulmonary arterial hypertension (PAH) WHO Group 1: requires right-heart catheterization results to confirm diagnosis for bosentan coverage
    Prescriber requirementPrescribed by or in consultation with a cardiologist or pulmonologist
    Documentation requiredRight-heart catheterization report included in medical record
    inv-222: BRAF V600 mutation-positive disease
    DefinitionBRAF V600 mutation-positive disease: tumor positive for BRAF V600 mutation required for certain Braftovi indications
    Documentation requiredBRAF V600 mutation status from an approved test must be provided
    Typical age restrictionIndications generally for adults 18 years and older
    inv-223: Hereditary Angioedema (HAE) due to C1-INH deficiency (Type I or II)
    DefinitionHAE Type I/II due to C1-INH deficiency: defined by low functional C1-INH (<50% of normal) and low serum C4 at baseline
    Documentation requiredBaseline functional C1-INH and serum C4 lab results must be in medical record for Haegarda prophylaxis
    Prescriber requirementPrescribed by or in consultation with an allergist/immunologist or HAE specialist
    inv-224: HAE with normal C1-INH (Type III)
    DefinitionHAE with normal C1-INH (Type III): diagnosis by positive genetic test (F12, ANGPT1, PLG, KNG1, HS3ST6, MYOF) OR family history with angioedema refractory to high-dose antihistamine for >=1 month
    Documentation requiredGenetic test result OR documented family history and treatment-refractory course must be in record
    Coverage noteApproved for prophylaxis when criteria met
    inv-225: Prerequisite Therapy Required
    DefinitionPrerequisite Therapy Required: patient must have inadequate response, intolerance, or contraindication to specified therapies (eg, SSRIs/SNRIs for OCD/panic; two of SNRI/SSRI/mirtazapine/bupropion for depression)
    ApplicationApplies to agents like clomipramine where step therapy is required
    Documentation requiredClinical documentation of prior therapy trials or intolerance must be provided
    inv-226: Objective ambulation measure
    DefinitionObjective ambulation measure: an objective test documenting impaired walking such as the timed 25-foot walk or MSWS-12
    ApplicationRequired for dalfampridine initial approval to document impaired ambulation in MS
    Documentation requiredTimed walk or MSWS-12 result included in medical record
    inv-227: EoE eosinophilic esophagitis
    DefinitionEoE (eosinophilic esophagitis): diagnosis requires endoscopic biopsy with >= 15 intraepithelial eosinophils per high-power field and exclusion of secondary causes
    Additional requirementsPatient must weigh >= 15 kg and complete an 8-week trial of prescription-strength PPI before approval
    Documentation requiredEndoscopy/biopsy report and PPI trial documented in medical record
    inv-228: ESA
    DefinitionESA: erythropoiesis-stimulating agent used in anemia management with indication-specific Hb thresholds for initiation and continuation
    Clinical thresholdsInitial Hb thresholds and continuation Hb limits vary by indication (eg, initial Hb <10 g/dL; continue if Hb <=12 g/dL)
    Documentation requiredHemoglobin and, when applicable, serum erythropoietin lab results must be included
    inv-229: Fabrazyme eligibility
    DefinitionFabrazyme eligibility: laboratory-confirmed deficient alpha-galactosidase A activity in leukocytes or fibroblasts OR pathogenic GLA gene variant
    Prescriber requirementPrescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist or lysosomal storage disorder specialist
    Documentation requiredEnzyme assay or genetic test results documented in medical record
    inv-230: Relapsing form of Multiple Sclerosis (MS)
    DefinitionRelapsing form of Multiple Sclerosis (MS): includes clinically-isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease
    ApplicationRequired medical information for fingolimod and glatiramer products
    Documentation requiredClinical diagnosis documentation in medical record
    inv-231: RET fusion-positive disease
    DefinitionRET fusion-positive disease: RET rearrangement or pathogenic RET mutation detected by an FDA-approved test required for Gavreto approval
    Documentation requiredRET testing result included in medical record
    Typical age limitsNSCLC patients generally 18 years and older; thyroid cancer limits may vary
    inv-232: Sensitizing EGFR mutation-positive NSCLC
    DefinitionSensitizing EGFR mutation-positive NSCLC: examples include exon 19 deletions, exon 21 L858R, L861Q, G719X, S768I detected by an approved test
    ApplicationRequired for gefitinib/erlotinib/Gilotrif approvals in advanced/metastatic NSCLC
    Documentation requiredEGFR mutation test report included in medical record
    inv-233: Relapsing MS
    DefinitionRelapsing MS: includes clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive MS
    Use caseReferenced for fingolimod and glatiramer coverage criteria requiring neurologist involvement
    Documentation requiredClinical diagnosis documentation in medical record
    inv-234: Prerequisite therapy (definition)
    DefinitionPrerequisite therapy: prior systemic regimens or conventional systemic treatments that must have been tried before approval for certain indications
    ApplicationExamples include prior chemotherapy, hydroxyurea, peginterferon, or other agents depending on indication
    Documentation requiredMedical record must document prior therapies tried and dates
    inv-235: PIK3CA-mutated breast cancer
    DefinitionPIK3CA-mutated breast cancer: breast cancer harboring a PIK3CA mutation detected by an approved test required for Itovebi use
    Documentation requiredPIK3CA mutation test result documented in medical record
    Treatment contextItovebi requires combination with palbociclib and fulvestrant per policy criteria
    inv-236: Higher-risk myelofibrosis
    DefinitionHigher-risk myelofibrosis: a myelofibrosis category referenced for Inrebic approval when patient has higher-risk disease
    Documentation requiredDiagnosis and risk classification documented in medical record per Inrebic criteria
    Age/coverage noteInrebic authorization typically for patients 18 years and older and duration 1 year